Jaguar Health announces $10.8 million registered direct offering
- BySeeking Alpha-
Jaguar Health upsizesat-the-market financing program by $15.3Mthe company established on October 5, 2020 with Ladenburg Thalmann for potential future...
Jaguar Health (JAGX) promoted20-year industry veteran Carol Lizak, an accomplished financial executive, to the expanded CFO role.
Investors always look for stocks with low P/E ratios as the measure indicates undervaluation. This ratio is obtained by dividing a stock’s current market price with its...
We are initiating research on Jaguar Health Inc (NASDAQ:JAGX), which is centered on the development and marketing of its drug crofelemer for diarrheal disorders. It is approved and...
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. The Company's other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.